Midkine and pleiotrophin: Two related proteins involved in development, survival, inflammation and tumorigenesis

被引:316
作者
Muramatsu, T [1 ]
机构
[1] Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, Aichi 4668550, Japan
关键词
cancer therapy; cell migration; cell survival; protein tyrosine phosphatase; tumor marker;
D O I
10.1093/oxfordjournals.jbchem.a003231
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Midkine (MK) and pleiotrophin (PTN) are low molecular weight proteins with closely related structures. They are mainly composed of two domains held by disulfide bridges, and there are three antiparallel beta-sheets in each domain. MK and PTN promote the growth, survival, and migration of various cells, and play roles in neurogenesis and epithelial mesenchymal interactions during organogenesis. A chondroitin sulfate proteoglycan, protein-tyrosine phosphatase zeta (PTPzeta), is a receptor for MK and PTN. The downstream signaling system includes ERK and PI3 kinase. MK binds to the chondroitin sulfate portion of PTPzeta with high affinity. Among the various chondroitin sulfate structures, the E unit, which has 4,6-disulfated N-acetylgalactosamine, provides the strongest binding site. The expression of MK and PTN is increased in various human tumors, making them promising as tumor markers and as targets for tumor therapy. MK and PTN expression also increases upon ischemic injury. MK enhances the migration of inflammatory cells, and is involved in neointima formation and renal injury following ischemia. MK is also interesting from the viewpoints of the treatment of neurodegenerative diseases, increasing the efficiency of in vitro development, and the prevention of HIV infection.
引用
收藏
页码:359 / 371
页数:13
相关论文
共 184 条
[11]  
Chaffey N., 2003, MOL BIOL CELL, V91, P401, DOI [DOI 10.1093/AOB/MCG023, 10.1093/aob/mcg023]
[12]   PLEIOTROPHIN TRANSFORMS NIH 3T3 CELLS AND INDUCES TUMORS IN NUDE-MICE [J].
CHAUHAN, AK ;
LI, YS ;
DEUEL, TF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (02) :679-682
[13]  
Choudhuri R, 1997, CANCER RES, V57, P1814
[14]   MITOGENIC PROPERTIES OF A NEW ENDOTHELIAL-CELL GROWTH-FACTOR RELATED TO PLEIOTROPHIN [J].
COURTY, J ;
DAUCHEL, MC ;
CARUELLE, D ;
PERDERISET, M ;
BARRITAULT, D .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 180 (01) :145-151
[15]  
CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358
[16]   Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin [J].
Czubayko, F ;
Schulte, AM ;
Berchem, GJ ;
Wellstein, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (25) :14753-14758
[17]   Pleiotrophin: A cytokine with diverse functions and a novel signaling pathway [J].
Deuel, TF ;
Zhang, N ;
Yeh, HJ ;
Silos-Santiago, I ;
Wang, ZY .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2002, 397 (02) :162-171
[18]   HB-GAM/pleiotrophin but not RIHB/midkine enhances chondrogenesis in micromass culture [J].
Dreyfus, J ;
Carvalho, NBD ;
Duprez, D ;
Raulais, D ;
Vigny, M .
EXPERIMENTAL CELL RESEARCH, 1998, 241 (01) :171-180
[19]  
FABRI L, 1992, BIOCHEM INT, V28, P1
[20]   STRUCTURAL CHARACTERIZATION OF NATIVE AND RECOMBINANT FORMS OF THE NEUROTROPHIC CYTOKINE MK [J].
FABRI, L ;
MARUTA, H ;
MURAMATSU, H ;
MURAMATSU, T ;
BURGESS, AW ;
NICE, EC .
JOURNAL OF CHROMATOGRAPHY, 1993, 646 (01) :213-225